Abstract: Disclosed herein are new salts and polymorphs of cethromycin for the treatment of diseases due to infection by bacteria and certain protozoans, including, for example, malaria, Babesosis, Toxoplasmosis, diarrheal disease, respiratory disease, sexually transmitted bacterial infections, and some bioterror bacteria, including, for example, plague, tularemia and post-inhalation anthrax. Also disclosed herein are new salts and polymorphs of cethromycin for the treatment of inflammatory diseases, including, for example, pelvic inflammatory disease, and peptic ulcer disease.

Abstract: A catalyst and methods for making the catalyst are provided. An exemplary catalyst includes the formula: MoaVbTec-TadOx. In this formula, a is 1.0, b is about 0.01 to about 0.3, c is about 0.01 to about 0.09, d is about 0.01 to about 0.05, and x is the number of oxygen atoms necessary to render the catalyst electronically neutral.

Abstract: Methods are provided provides a method for preparing a catalyst for oxidative dehydrogenation. An exemplary method includes forming a slurry including oxides of molybdenum, tantalum oxide, and tellurium and adding VOSO4 to the slurry. Citric acid, oxalic acid, and ethylene glycol are added to the slurry. The slurry is transferred to an autoclave, and the autoclave is heated to form a catalyst precursor. The catalyst precursor formed in the autoclave is isolated and calcined to form the catalyst.

Abstract: A catalyst, useful for oxidative dehydrogenation of ethane, comprising molybdenum, vanadium, tellurium, tantalum, and oxygen, prepared using a stage hydrothermal synthesis procedure, is provided. The catalyst comprises from 30 to 50 wt. % amorphous content and may be combined with a support/carrier material to form a catalyst material. The described catalysts and catalyst materials demonstrate high selectivity for ethylene at higher temperatures, show little to no decline in conversion and selectivity over time, and do not appear to be sensitive to low residual oxygen concentrations.

Abstract: Disclosed herein are new salts and polymorphs of cethromycin for the treatment of diseases due to infection by bacteria and certain protozoans, including, for example, malaria, Babesosis, Toxoplasmosis, diarrheal disease, respiratory disease, sexually transmitted bacterial infections, and some bioterror bacteria, including, for example, plague, tularemia and post-inhalation anthrax. Also disclosed herein are new salts and polymorphs of cethromycin for the treatment of inflammatory diseases, including, for example, pelvic inflammatory disease, and peptic ulcer disease.

Abstract: Shaped catalyst compositions and methods for making and using the shaped catalyst compositions are provided. In an exemplary a catalyst active phase includes a MoVTeTaOx catalyst. The composition also includes a support phase, wherein the support phase includes fumed silica, and wherein the catalyst active phase and support phase form a heterogeneous mixture.

Abstract: Shaped catalyst compositions and methods for making and using the shaped catalyst compositions are provided. In an exemplary a catalyst active phase includes a MoVTeNbOx catalyst. The composition also includes a support phase, wherein the support phase includes fumed silica, and wherein the catalyst active phase and support phase form a heterogeneous mixture.

Abstract: This document relates to oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, beryllium, oxygen, and optionally aluminum.

Abstract: Mixed metal oxide catalysts having an amorphous content of not less than 40 wt. % are prepared by calcining the catalyst precursor fully or partially enclosed by a porous material having a melting temperature greater than 600° C. in an inert container including heating the catalyst precursor at a rate from 0.5 to 10° C. per minute from room temperature to a temperature from 370° C. to 540° C. under a stream of pre heated gas chosen from steam and inert gas and mixtures thereof at a pressure of greater than or equal to 1 psig having a temperature from 300° C. to 540° C. and holding the catalyst precursor at that temperature for at least 2 hours and cooling the catalyst precursor to room temperature.

Abstract: This document relates to oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, beryllium, oxygen, and optionally aluminum.

Abstract: This document relates to oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, and iron; oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, and aluminum; and oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, iron, and aluminum.

Abstract: This document relates to oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, and iron; oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, and aluminum; and oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, iron, and aluminum.

Abstract: Provided in this disclosure are catalyst compositions. The catalyst compositions include an oxidative dehydrogenation catalyst that includes a mixed metal oxide having the empirical formula: Mo1.0V0.12-0.49Te0.05-0.17Nb0.10-0.20AlcOd wherein c is from 0 to 2.0 and d is a number to satisfy the valence of the oxide. The compositions are at least 40 wt. % amorphous as measured by XRD. The disclosure also provides methods of making the compositions.

Abstract: This document relates to oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, and iron; oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, and aluminum; and oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, iron, and aluminum.

Abstract: Catalysts and Methods for large-scale production of the catalysts are provided. An exemplary catalyst composition includes molybdenum, vanadium, tellurium, niobium, oxygen. In the catalyst composition, the molar ratio of molybdenum to vanadium is from 1:0.05 to 1:0.60, the molar ratio of molybdenum to tellurium is from 1:0.01 to 1:0.30, and the molar ratio of molybdenum to niobium is from 1:0.01 to 1:0.40. Oxygen is present at least in an amount to satisfy the valency of any present metal oxides, and composition includes less than 1.0 wt. % of sulfur.

Abstract: A catalyst, useful for oxidative dehydrogenation of ethane, comprising molybdenum, vanadium, tellurium, tantalum, and oxygen, prepared using a stage hydrothermal synthesis procedure, is provided. The catalyst comprises from 30 to 50 wt. % amorphous content and may be combined with a support/carrier material to form a catalyst material. The described catalysts and catalyst materials demonstrate high selectivity for ethylene at higher temperatures, show little to no decline in conversion and selectivity over time, and do not appear to be sensitive to low residual oxygen concentrations.

Abstract: Disclosed herein are new salts and polymorphs of cethromycin for the treatment of diseases due to infection by bacteria and certain protozoans, including, for example, malaria, Babesosis, Toxoplasmosis, diarrheal disease, respiratory disease, sexually transmitted bacterial infections, and some bioterror bacteria, including, for example, plague, tularemia and post-inhalation anthrax. Also disclosed herein are new salts and polymorphs of cethromycin for the treatment of inflammatory diseases, including, for example, pelvic inflammatory disease, and peptic ulcer disease.

Abstract: Oxidative dehydrogenation catalysts for converting lower paraffins to alkenes such as ethane to ethylene when prepared as an agglomeration, for example extruded with supports comprising slurries of Nb2O5.

Abstract: Provided in this disclosure are catalyst compositions. The catalyst compositions include an oxidative dehydrogenation catalyst that includes a mixed metal oxide having the empirical formula: Mo1.0V0.12-0.49Te0.05-0.17Nb0.10-0.20AlcOd wherein c is from 0 to 2.0 and d is a number to satisfy the valence of the oxide. The compositions are at least 40 wt. % amorphous as measured by XRD. The disclosure also provides methods of making the compositions.

Abstract: Mixed metal oxide catalysts having an amorphous content of not less than 40 wt. % are prepared by calcining the catalyst precursor fully or partially enclosed by a porous material having a melting temperature greater than 600° C. in an inert container including heating the catalyst precursor at a rate from 0.5 to 10° C. per minute from room temperature to a temperature from 370° C. to 540° C. under a stream of pre heated gas chosen from steam and inert gas and mixtures thereof at a pressure of greater than or equal to 1 psig having a temperature from 300° C. to 540° C. and holding the catalyst precursor at that temperature for at least 2 hours and cooling the catalyst precursor to room temperature.